Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Lung Neoplasms 2Recurrence 1Non-Small Cell Lung Cancer ALK-positive 1Neurofibromatosis 1 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Hereditary Sensory and Autonomic Neuropathies 1Colorectal Neoplasms 1Brain Neoplasms 1Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer 1Advanced Non-Small Cell Lung Cancer 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

AZD 6244 7trametinib 4mirdametinib 2fludarabine 2Inhalation 2Acetylcysteine 2thymoglobulin 1talimogene laherparepvec 1omipalisib 1lorlatinib 1fludarabine phosphate 1encorafenib 1dabrafenib 1binimetinib 1abemaciclib 1Vincristine 1Specimen Handling 1Sirolimus 1Rituximab 1Radiation 1N-monoacetylcystine 1Melphalan 1Magnetic Resonance Spectroscopy 1Levetiracetam 1Lasers, Solid-State 1Lasers 1Injections 1Deoxycholic Acid 1Cytarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × lorlatinib × 90 days × Clear all
NCT04800822 2026-06-04

PF-07284892 in Participants With Advanced Solid Tumors

Pfizer

Phase 1 Terminated
53 enrolled
CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡